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2854Objective: Superior aortic valve hemodynamic performance can accelerate left ventricular mass regression and
enhance survival and functional status after surgical aortic valve replacement. This can be achieved by rapid
deployment aortic valve replacement using a subannular balloon-expandable stent frame, which functionally
widens and reshapes the left ventricular outflow tract, to ensure a larger effective orifice area compared with con-
ventional surgical valves. We report the intermediate-term follow-up data from a large series of patients enrolled
in the Surgical Treatment of Aortic Stenosis With a Next Generation Surgical Aortic Valve (TRITON) trial.
Methods: In a prospective, multicenter (6 European hospitals), single-arm study, 287 patients with aortic
stenosis underwent rapid deployment aortic valve replacement using a stented trileaflet bovine pericardial bio-
prosthesis. Core laboratory echocardiography was performed at baseline, discharge, and 3 months, 1 year, and 3
years after rapid deployment aortic valve replacement.
Results: The mean patient age was 75.7  6.7 years (range, 45-93; 49.1% women). The mean aortic valve
gradient significantly decreased from discharge to 3 years of follow-up. Themean effective orifice area remained
stable from discharge to 3 years. At 1 year, the left ventricular mass index had decreased by 14% (P<.0001) and
at 3 years by 16% (P<.0001) compared with at discharge. The prevalence of severe patient-prosthesis mismatch
was 3% at discharge and remained stable during the follow-up period.
Conclusions: In a large series of elderly patients with symptomatic severe aortic stenosis, rapid deployment
aortic valve replacement using a subannular balloon-expandable stent frame demonstrated excellent hemody-
namic performance and significant left ventricular mass regression. With continued follow-up, future studies
will establish whether these favorable structural changes correlate with improvement in long-term survival
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The Journal of Thoracic and Cardiovascular SurElevated transvalvular gradients can contribute to persistent
left ventricular (LV) hypertrophy and diastolic dysfunction
after aortic valve replacement (AVR), which can contribute
to patient-prosthesismismatch (PPM) and decreased survival.1
Superior aortic valve hemodynamic performance can accel-
erate LV mass regression and enhance long-term survival
and functional status after surgical AVR.2-6 Sutureless and
rapid deployment aortic valve prostheses have recently been
introduced into clinical practice in Europe and Asia, and
several studies have demonstrated early safety and efficacy.7-9
A rapid deployment AVR (RDAVR) system with a
subannular balloon-expandable stent frame, which could
lead to widening of the LV outflow tract (valve inflow)
and a larger effective orifice area (EOA) compared with
conventional surgical valves, has been investigated in an
ongoing multicenter trial.10 We report the intermediate-
term follow-up data from a large series of patients enrolled
in a clinical trial of RDAVR, with a particular focus on the
hemodynamic outcomes.gery c December 2014
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
CABG ¼ coronary artery bypass grafting
EOA ¼ effective orifice area
LV ¼ left ventricular
NYHA ¼ New York Heart Association
PARTNER ¼ Placement of Aortic Transcatheter
Valves
PPM ¼ patient-prosthesis mismatch
PVL ¼ paravalvular leak
RDAVR ¼ rapid deployment aortic valve
replacement
TRITON ¼ Surgical Treatment of Aortic Stenosis
With a Next Generation Surgical
Aortic Valve
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Study Population
The Surgical Treatment of Aortic Stenosis With a Next Generation Sur-
gical Aortic Valve (TRITON) trial (ClinicalTrials.gov no. NCT01445171)
was a prospective, nonrandomized, single-arm, multicenter trial conducted
in 6 European hospitals. The study design and methods have been previ-
ously described by Kocher and associates.10 A total of 295 consecutive pa-
tients with aortic stenosis or aortic stenosis insufficiency requiring elective
AVRwith or without concomitant coronary artery bypass grafting (CABG)
were enrolled; 287 of these were treated with the Edwards Intuity Valve
System (model 8300A; Edwards Lifesciences Corp, Irvine, Calif), a
stented trileaflet bovine pericardial bioprosthesis with a balloon-
expandable, cloth-covered skirt frame at the inflow aspect (Figure 1).
The ethics committee of each participating center reviewed and approved
the study protocol, and all patients provided written informed consent.
RDAVR System
RDAVRwith the Edwards Intuity Valve System was performed through
either a minimally invasive technique or full sternotomy, as previously
described by Kocher and associates.10 After standard aortotomy, the native
aortic valve leaflets were removed and annular calcium was debrided using
conventional techniques. Three equidistant guiding sutures were placed
through the nadir of the aortic annulus and then through the corresponding
positions on the valve sewing ring. Using the delivery system, the valvewas
lowered onto the annulus using the guiding sutures. Once the valve was
seated, the balloon catheter was expanded to rapidly deploy the valve. After
deployment, the delivery system was removed, the guiding sutures were
tied down, and the aortotomy was closed.
Endpoints
The safety endpoints included valve-related mortality, thromboembolic
events, study valve thrombosis, major bleeding events, paravalvular leakage,
and prosthetic valve endocarditis. The performance endpoints included tech-
nical success, procedural success, change in logistic EuroSCORE I, improve-
ment in New York Heart Association (NYHA) functional classification, and
valve hemodynamic performance. Embolism was defined as a free-flowing
blood clot or lesionmaterial located in the systemic or pulmonary circulation
and occurring in the absence of infection after the immediate perioperative
period. Valve thrombosis was defined as a blood clot not associated with
infection, causing dysfunction of the heart valve substitute. A bleeding event
was defined as any episode ofmajor internal or external bleeding that caused
death, hospitalization, or permanent injury (eg, vision loss) or necessitated
transfusion. Major paravalvular leak (PVL) was defined as paravalvularThe Journal of Thoracic and Carregurgitation graded asþ3 moderate orþ4 severe according to the core lab-
oratory evaluation of the echocardiogram. Endocarditis is an inflammation or
infection of the endocardium (ie, the inner lining of the heart muscle) and,
most commonly, the heart valves. It is typically caused by a bacterial infec-
tion but can be caused by fungus. Technical success was defined as delivery
and deployment of the study valvewithin 2 attempts. Procedural success was
defined as technical success and the absence of complications requiring de-
vice reoperation, permanent pacemaker implantation (with baseline sinus
rhythm and no conduction issues), or death. Additional details on these def-
initions have been previously reported by Kocher and associates.10
Follow-up
The clinical and echocardiographic follow-up data were collected per
protocol at baseline, discharge, 3 and 12months postoperatively, and yearly
thereafter for 5 years. All hemodynamic data were reviewed by an indepen-
dent echocardiographic core laboratory (Columbia University Medical
Center, New York, NY). Complications were adjudicated by an indepen-
dent clinical events committee. Aggregate follow-up data were reviewed
by an independent data safety monitoring board.
Data Management
As the study sponsor, Edwards Lifesciences managed the collection and
monitoring of the data; however, it did not have a role in the interpretation
of the data.
Statistical Analysis
Continuous variables are summarized as the mean standard deviation
and categorical variables as percentages. Complications were summarized
for the early (30 days after the index procedure) and late (>30 days after
the index procedure) periods. Early rates were calculated as the number of
events divided by the number of patients receiving the study valve. Linear-
ized rates for complications were calculated for the late period as the num-
ber of late events divided by the number of late patient-years (482.3 late
patient-years). Inference statistics comparing continuous variables among
themeasurement points were made using a linear mixed effect model. Two-
sided tests were used, and a type I error significance level of 0.05 was
considered. All data were from a data extract date of February 14, 2014.
RESULTS
Baseline Patient and Echocardiographic
Characteristics
The baseline patient and echocardiographic characteris-
tics are presented in Table 1. In total, 287 patients (mean
age, 75.7 6.7 years; 49.1%women) received the Edwards
Intuity valve (Edwards Lifesciences) with a total accumu-
lated follow-up of 482.3 late patient-years. The mean
follow-up for all enrolled subjects was 1.8  0.9 years.
The mean logistic EuroSCORE I was 8.4  6.7, with
53.2% of the patients (150 of 282) in NYHA class III and
IV. The mean body mass index was 28.0  4.3 kg/m2,
with a mean preoperative aortic annulus diameter of
23.0  2.2 mm. The mean prosthesis size was 23.1  1.9
mm; the median prosthesis size was 23 mm. The prosthesis
size distribution is listed in Table 1. After 23 mm, the fre-
quency of using the 21- and 25-mm devices was similar.
Early and Late Morbidity, Mortality, and Functional
Status
Early (30-day) all-cause mortality was 1.7% (heart
failure in 1, cardiogenic shock in 2, thromboembolic eventdiovascular Surgery c Volume 148, Number 6 2855
FIGURE 1. A, Rapid deployment aortic valve: Edwards Intuity Valve
System (model 8300A). B, Echocardiographic image of implanted Ed-
wards Intuity Valve System (model 8300A).
TABLE 1. Clinical and echocardiographic variables at baseline
Variable Value
Age (y) 287; 75.7  6.7*
Sex
Female 49.3 (141/286)
Male 50.7 (145/286)
Logistic EuroSCORE (%) 282; 8.4  6.7
NYHA classification
I 5.0 (14/282)
II 41.8 (118/282)
III 50.0 (141/282)
IV 3.2 (9/282)
Echocardiographic variables
Body surface area (m2) 286; 1.9  0.2
Body mass index (kg/m2) 286; 28.0  4.3
Aortic annulus diameter (mm) 238; 23.0  2.2
Indexed annulus diameter (mm/m2) 237; 12.2  1.4
LVEF (%) 188; 61.2  11.1
Valve size distribution (mm)
19 2.1 (6/287)
21 29.6 (85/287)
23 34.5 (99/287)
25 27.2 (78/287)
27 6.6 (19/287)
Valve size
Patients (n) 287
Mean  SD (mm) 23.1  1.9
Median (mm) 23
Data presented as number of patients; mean SD or% (n/N), unless otherwise noted.
NYHA, New York Heart Association; LVEF, left ventricular ejection fraction;
SD, standard deviation; EuroSCORE, European System for Cardiac Operative Risk
Evaluation. *Baseline data missing for 1 subject.
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Early complications included thromboembolic events in
13 patients (4.5%), including stroke in 8 (2.8%), major
bleeding events in 7 (2.4%), major PVL (>2þ) in 2
(0.7%), and valve explantation in 4 (1.4%). The causes
of early explantation were reported as bleeding during
and after the procedure. No early cases of valve-related
thrombosis or endocarditis developed (Table 2). The early
event rate for renal dysfunction, reoperation for bleeding,
deep sternal wound infection, and respiratory dysfunction
was 5.2% (n ¼ 15), 7.7% (n ¼ 22), 3.1% (n ¼ 9), and
2.8% (n ¼ 8), respectively.
Late (>30-day) all-cause mortality was 3.7% (n ¼ 18)
per late-patient year for all patients (Table 2), with 2 deaths
adjudicated as valve-related. The causes of late mortality
were respiratory failure in 2, infection in 2, ruptured aortic
aneurysm in 1, cancer in 3, myocardial infarction in 2,
stroke in 1, multisystem organ failure in 2, cardiac arrest
in 1, endocarditis in 1, cerebral hemorrhage due to head
trauma in 1, sepsis in 1, and natural death in 1. Late throm-
boembolic events were reported as 1.7% (n ¼ 8) per late-
patient year (4 events led to a stroke), and late major PVL
events were reported as 1.2% (n ¼ 6) per late-patient
year. Late endocarditis events were reported in 0.2%
(n¼ 1) of the patients. Valve explants occurred in 3 patients
(0.6% per late patient-year) due to major PVL, endocardi-
tis, and aortic root aneurysm in 1 patient each. No cases of2856 The Journal of Thoracic and Cardiovascular Survalve-related thrombosis, hemolysis, or structural valve
deterioration were reported.
At the 3-month and 1-year follow-up points, NYHA
functional class improvement was observed in 72.6% and
75.1% of the population, respectively, and 24.7% and
22.9% of the patients reported the same NYHA class as
at baseline (Table 3). Among the patients in NYHA class
III or IV, 90% (118 of 131) had improved 1 functional
class at 1 year postoperatively.Hemodynamic Outcomes
Core laboratory echocardiographic data were obtained at
discharge and the 3-month, 1-year, and 3-year follow-up in-
tervals. The mean gradient at 3 months, 1 year, and 3 years
was 9.0  3.4, 9.0  3.6, and 8.7  4.1 mm Hg, respec-
tively, significantly lower than at discharge (P<.0001 for
discharge vs 3 months and 1 year, P ¼ .0031 for discharge
vs 3 years). The LV mass at 3 years was 178.5  42.8 g,
lower than that at 3 months and 1 year postoperatively
(196.6 49.8 and 184.3 47.7 g, respectively). In contrast,
the LV mass index at 3 years was significantly lower than at
discharge (P< .0001). The mean EOA and indexed EOA
remained unchanged throughout the follow-up period atgery c December 2014
TABLE 2. Early and late safety events
Event
Early
(30 d; n ¼ 287)
Late events
(>30 d; n ¼ 482.32)
Mortality 1.7 (5) 3.7 (18)
Thromboembolism 4.5 (13) 1.7 (8)
Valve thrombosis 0.0 (0) 0.0 (0)
Major bleeding 2.4 (7) 0.8 (4)
Endocarditis 0.0 (0) 0.2 (1)
Major paravalvular leak (>2þ) 0.7 (2) 1.2 (6)
Explantation 1.4 (4) 0.6 (3)
Renal failure or dysfunction 5.2 (15) 1.7 (8)
Reoperation for bleeding 7.7 (22) 0.0 (0)
Deep sternal wound infection 3.1 (9) 0.6 (3)
Respiratory dysfunction 2.8 (8) 0.4 (2)
Data presented as% (n) for early events and%/late patient-year (n) for late events.
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The mean gradient and EOA stratified according to valve
size are presented in Table 5.
Freedom from major PVL (>þ2) was 98% at each of
the follow-up intervals (Table 6). The incidence of severe
PPM (indexed EOA  0.65 cm2/m2) among all subjects
was 3% at each of the follow-up intervals (Table 7). As
previously described by Clavel and colleagues,11 a small
aortic annulus was defined as an annular diameter of 20
mm. In the subgroup of patients with a small aortic annulus,
a greater prevalence of severe PPM was seen at discharge
(20%; 2 of 10) and 1 year (15%; 2 of 13; Table 7). At 3
months and 3 years, the incidence of severe PPM in this
small aortic annulus subgroup was 8% (1 of 12) and 0%
(0 of 5), respectively. No difference was seen in the inci-
dence of severe PPM in the subset of patients with an aortic
annulus diameter of>20 mm (P¼ .84) across all follow-up
intervals.DISCUSSION
The Edwards Intuity Valve System was uniquely
designed to facilitate RDAVR in patients with aorticTABLE 3. Summary of NYHA improvement from 3 months to 1 year
Follow-up
NYHA class Total
(n ¼ 287)I II III IV
3 mo
Patients (n) 12 111 128 8 259
Improved 0 (0.0) 74 (66.7) 106 (82.8) 8 (100.0) 188 (72.6)
Same 8 (66.7) 34 (30.6) 22 (17.2) 0 (0.0) 64 (24.7)
Worse 4 (33.3) 3 (2.7) 0 (0.0) 0 (0.0) 7 (2.7)
1 y
Patients (n) 12 106 125 6 249
Improved 0 (0.0) 69 (65.1) 112 (89.6) 6 (100.0) 187 (75.1)
Same 9 (75.0) 35 (33.0) 13 (10.4) 0 (0.0) 57 (22.9)
Worse 3 (25.0) 2 (1.9) 0 (0.0) 0 (0.0) 5 (2.0)
Data presented as n (%). The number of patients changed over time because subjects
exited the study owing to death, explantation, or other reasons and represents the
number of subjects with both baseline and follow-up NYHA data. NYHA, New
York Heart Association.
The Journal of Thoracic and Carstenosis. To properly evaluate its safety and efficacy, a pro-
spective, multicenter, single-arm study was undertaken—
the TRITON Trial. The Intuity valve was implanted in
287 patients in 6 European centers. At 3 years, the data
demonstrated a low mean transvalvular gradient (mean,
8.7 mm Hg in all patients) and significant LV mass regres-
sion (DLV mass index compared with discharge, 16%).
Compared with the standard surgical bioprostheses,12 the
Intuity could be associated with larger EOAs in smaller
valve sizes, a lower risk of PPM, and a low rate of moderate
or severe postoperative PVL. The notable hemodynamic re-
sults were also accompanied by a significant improvement
in functional status, in particular, in highly symptomatic pa-
tients. At baseline, 53% of patients were in NYHA class III
or IV, and improvement in functional class was observed in
90% of these patients during the follow-up period.
RDAVR using the Edwards Intuity Valve System has
been demonstrated to be safe. We previously reported the
1-year outcomes of the initial 152 patients treated using
the first-generation Intuity Valve System (model 8300A;
Edwards Lifesciences) and found a mortality rate of
2.1%, despite a mean patient age of 75.5 years.10 Nearly
60% of the cases were AVR only and 25% were AVR
plus CABG. The operative approach involved a minimally
invasive incision (ie, upper hemisternotomy or right ante-
rior thoracotomy) in nearly one half of the patients who un-
derwent isolated AVR. Technical device success was
achieved in 96% (146 of 152) of the patients. For isolated
AVR, the crossclamp and cardiopulmonary time was 41
and 66 minutes and for AVR plus CABG, 60 and 96 mi-
nutes, respectively. Early (30-day) mortality and compli-
cations were uncommon and included valve-related
mortality in 1.4% of the patients, thromboembolism in
2.7%, valve explantation in 1.4%, and reoperation for
bleeding in 0.7%.
The present report has extended these observations to 287
patients, of whom 138 were treated using the second-
generation Intuity Valve System (model 8300AB; Edwards
Lifesciences). In the second-generation device, 3 minor
design modifications were made to enhance seating during
implantation. First, the number of cloth layers on the frame
was reduced and the cloth was shifted down closer to the
inflow edge of the annulus frame. With the cloth on the
annulus frame moved down, the resulting tissue annulus
diameter was reduced by 1 mm. Second, the single,
crimped cloth-covered, expandable stainless steel frame
was double crimped to further reduce the implant profile.
Third, the valve holder is now cusp-mounted instead of
commissural-mounted to increase the visibility for the nadir
suture markers.
In the extended cohort of 287 patients, 55% underwent
AVR only and 27% AVR plus CABG. Minimally invasive
incisions were used in 55% of the 158 patients undergoing
isolated AVR. In contrast, analysis of the national cardiacdiovascular Surgery c Volume 148, Number 6 2857
TABLE 4. Echocardiographic data at follow-up
Variable
Follow-up P value
Discharge 3 mo 1 y 3 y Overall
Discharge
vs 3 mo
Discharge
vs 1 y
Discharge
vs 3 y
EOA (cm2) 1.7  0.2 (178) 1.7  0.2 (204) 1.7  0.2 (211) 1.7  0.2 (58) .1579 .5696 .2367 .0286
EOA index (cm2/m2) 0.9  0.1 (164) 0.9  0.1 (195) 0.9  0.1 (186) 0.9  0.1 (47) .0730 .0158 .2940 .8804
Mean gradient (mm Hg) 10.7  4.2 (226) 9.0  3.4 (224) 9.0  3.6 (230) 8.7  4.1 (59) <.0001 <.0001 <.0001 .0031
Cardiac output (L/min) 5.1  1.1 (189) 4.8  1.1 (211) 4.8  1.1 (215) 4.6  1.0 (60) .0002 <.0001 .0007 .0052
Septal thickness (mm) 13.0  1.8 (148) 11.8  1.6 (197) 11.5  1.5 (216) 11.2  1.2 (57) <.0001 <.0001 <.0001 <.0001
Posterior thickness (mm) 12.5  1.6 (141) 11.5  1.5 (194) 11.0  1.3 (210) 10.6  1.0 (55) <.0001 <.0001 <.0001 <.0001
LV mass (g) 217.9  62.3 (100) 196.6  49.8 (161) 184.3  47.7 (178) 178.5  42.8 (44) <.0001 <.0001 <.0001 <.0001
LV mass index (g/m2) 116.0  31.9 (92) 105.0  23.4 (155) 99.2  23.3 (162) 97.5  18.9 (38) <.0001 <.0001 <.0001 <.0001
Data presented as mean  standard deviation. P values and pairwise comparisons versus discharge were from longitudinal analyses. EOA, Effective orifice area; LV, left ven-
tricular.
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Cardiovascular Surgery reported that partial sternotomy
constituted<20% (2168 of 11,906) of all isolated surgical
AVR procedures in 2012.13 The technical success rate
improved to >97% in the present study with increased
experience and improved training. Early and late (>30-
day) mortality and complications remained relatively con-
stant, including an all-cause mortality rate of 1.7% and
3.7% per patient-year and valve-related mortality rate of
1.0% and 0.4% per patient-year, respectively. These excel-
lent outcomes support the clinical safety of the Edwards In-
tuity Valve System and could promote its use for minimally
invasive surgery.
When deciding which bioprosthetic valve to select for
an individual patient, an important consideration is the
long-term durability. Technological advances in bovine
pericardial tissue treatment have been associated with
improved valve durability. In 1985, the XenoLogiXTABLE 5. Effective orifice area and mean gradient stratified by valve size
Valve size (mm) Discharge (n ¼ 265) 3 mo (
EOA (cm2)
Overall 1.7  0.2 1.7 
Valve size (mm)
19 1.3  0.2 (2) 1.4 
21 1.6  0.2 (50) 1.6 
23 1.8  0.2 (63) 1.7 
25 1.8  0.2 (53) 1.8 
27 1.8  0.2 (10) 1.9 
Mean gradient (mm Hg)
Overall 10.7  4.2 9.0 
Valve size (mm)
19 25.0  2.4 (5) 18.6 
21 10.7  3.3 (66) 9.2 
23 10.6  3.5 (80) 8.9 
25 9.9  4.1 (60) 8.5 
27 9.0  3.8 (15) 6.8 
Data presented as mean standard deviation; data in parentheses represent the number of su
variables were evaluable. EOA, Effective orifice area.
2858 The Journal of Thoracic and Cardiovascular Sur(Edwards Lifesciences) tissue treatment process was intro-
duced, which used ethanol and surfactant to extract>90%
of phospholipids from pericardial tissue after glutaralde-
hyde fixation. The reported clinical experience with Xeno-
LogiX has been very good. McClure and associates14
reported on 1000 patients who had undergone AVR with
the XenoLogiX-treated Carpentier-Edwards Perimount
and been followed up for 17 years. The actuarial freedom
from structural valve deterioration at 15 years was 89%
for patients aged 65 to 75 years and 99.5% for patients
>75 years. In another study, Forcillo and associates15 fol-
lowed up 2405 patients who had undergone AVR using
the Carpentier-Edwards Perimount during a 25-year period.
The actuarial freedom from reoperation for structural valve
deterioration was 95% at 10 years and 90% at 15 years for
patients aged 60 to 70 years and 99% at 10 years in patients
>70 years. Given that the Carpentier-Edwards Perimount
bioprosthesis is a core component of the Edwards IntuityFollow-up point
n ¼ 253) 1 y (n ¼ 249) 3 y (n ¼ 62)
0.2 1.7  0.2 1.7  0.2
0.2 (5) 1.3  0.1 (2) 1.5 — (1)
0.2 (62) 1.6  0.2 (68) 1.6  0.3 (22)
0.2 (73) 1.7  0.2 (72) 1.7  0.1 (19)
0.2 (52) 1.8  0.2 (52) 1.8  0.2 (14)
0.2 (12) 1.9  0.2 (17) 1.7  0.0 (2)
3.4 9.0  3.6 8.7  4.1
5.4 (6) 17.0  4.2 (5) 12.6 — (1)
2.9 (67) 9.9  3.2 (69) 10.0  4.1 (22)
2.9 (78) 9.0  3.6 (79) 7.2  3.2 (20)
3.2 (57) 8.2  3.1 (60) 9.1  4.7 (14)
1.5 (16) 6.2  1.5 (17) 5.8  1.4 (2)
bjects who completed an echocardiographic examination at the indicated visit; not all
gery c December 2014
TABLE 6. Paravalvular aortic regurgitation data at follow-up
Severity
Follow-up point
Discharge 3 mo 1 y 3 y
0 (None) 69.6 (179) 64.9 (163) 62.9 (156) 54.8 (34)
þ1 (Trivial/trace) 25.3 (65) 28.7 (72) 30.2 (75) 37.1 (23)
þ2 (Mild) 3.9 (10) 4.4 (11) 5.6 (14) 6.5 (4)
þ3 (Moderate) 0.8 (2) 1.6 (4) 1.2 (3) 1.6 (1)
þ4 (Severe) 0.4 (1) 0.4 (1) 0.0 (0) 0.0 (0)
Data presented as% (n).
TABLE 7. Effective orifice area index and incidence of severe patient-
prosthesis mismatch by stratified by aortic annular size
Variable
Follow-up point
Discharge 3 mo 1 y 3 y
All subjects
EOAi (cm2/m2) 0.9  0.1 0.9  0.1 0.9  0.1 0.9  0.1
Severe PPM 3 (5/164) 2 (4/195) 3 (6/186) 2 (1/47)
Mean gradient (mm Hg) 10.7  4.2 9.0  3.4 9.0  3.6 8.7  4.1
Annular size 20 mm
EOAi (cm2/m2) 0.8  0.1 0.9  0.2 0.8  0.1 0.9  0.2
Severe PPM 20 (2/10) 8 (1/12) 15 (2/13) 0 (0/5)
Mean gradient (mm Hg) 11.2  3.7 8.6  3.0 9.8  3.3 6.4  3.5
Annular size>20 mm
EOAi (cm2/m2) 0.9  0.1 0.9  0.1 0.9  0.1 0.9  0.1
Severe PPM 2 (3/131) 1 (2/151) 2 (3/144) 3 (1/32)
Mean gradient (mm Hg) 10.8  4.4 9.0  3.4 8.9  3.7 8.5  4.1
Data presented as mean standard deviation or% (n/N). EOAi, Effective orifice area
index; PPM, patient-prosthesis mismatch.
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long-term durability for our RDAVR cohort.
In addition to long-term durability, another important
factor influencing valve choice is hemodynamic perfor-
mance, with the primary goal being to avoid PPM. First
described by Rahimtoola4 in 1978, PPM occurs when the
EOA of the implanted prosthetic valve is less than that of
a normal human valve. The adverse effects of severe PPM
include less improvement in heart failure symptoms and
functional class,5 impaired exercise capacity,2 reduced LV
mass regression,5,6 and greater early (30-day) and interme-
diate (>5-year) mortality rates.3,5 In a study of 2576 patients
who survived AVR, Mohty and associates3 found that se-
vere PPM (defined as an indexed EOA of 0.65 cm2/m2)
was associated with decreased 5- and 10-year survival
(74% and 40%, respectively), significantly worse than
those for patients with mild or no PPM (5- and 10-year sur-
vival rate, 84% and 61%, respectively).
The limitations inherent in calculating the EOA using the
continuity equation, in particular, the operator-dependent
echocardiographic measurement of the LV outflow tract
diameter, have made comparisons of different valve studies
difficult.16 This issue can be reconciled, however, using an
echocardiographic core laboratory, which will reduce the
variability and enhance the interpretation of the echocardio-
graphic results. In the present study, the indexed EOA and
rate of severe PPM were calculated by the echocardio-
graphic core laboratory as 0.9 cm2/m2 and 3% (6 of 186)
at 1 year. For perspective, Hahn and associates17 reported
the echocardiographic core laboratory substudy of the
Placement of Aortic Transcatheter Valves (PARTNER) trial
cohort A, which included a surgical AVR control group. The
rate of severe PPM among the 142 AVR patients from their
study was nearly 30% (42 of 142) at 1 year. Although both
groups had severe aortic stenosis, the baseline characteris-
tics and echocardiographic findings of the patients in the
PARTNER trial depicted a higher risk population with fea-
tures predictive of postoperative PPM, such as advanced
age, coronary artery disease, diabetes, and renal failure.6
Nevertheless, it is unlikely that these differences alone suf-
ficiently explain the 10-fold increase in severe PPM.
According to Pibarot and Dumesnil,18 2 major factors
contribute to PPM: (1) pathologic changes that characterize
aortic stenosis (ie, annular calcification and fibrosis, whichThe Journal of Thoracic and Carrestrict the diameter of the bioprosthetic implant); and (2)
the structural support of the stented bioprosthesis, which oc-
cupies space within the aortic root and reduces the EOA
available for blood flow. Because the Edwards Intuity valve
is built around a Carpentier-Edwards Perimount bio-
prosthesis, one could expect a similar PPM rate to that
observed from conventional AVR series. However, the
very low rate of severe PPM observed in the present study
suggests another factor might be contributing to the hemo-
dynamic performance of the Intuity valve. The balloon-
expandable, cloth-covered stent frame sits in a subannular
position, where it might, hypothetically, optimize the flow
characteristics through the valve inlet by widening and re-
shaping the LVoutflow tract. Additional studies, including
magnetic resonance imaging flow assessment, are required
to more fully investigate this hypothesis.
Significant PVL is associatedwith an increased risk of late
mortality after AVR. Kodali and associates19 reported on 348
patients at high risk for surgery and subsequently randomized
to transcatheter aortic valve replacement in the PARTNER
Trial. The rate of moderate or severe PVL after transcatheter
aortic valve replacement in these patients was 7.0% at 1 year
and 6.9% at 2 years. Moreover, the presence of moderate or
severe PVL was associated with significantly greater late
mortality than in patients without PVL. In contrast, surgical
AVR has usually been associated with an extremely low
rate of postoperative PVL. Of the 351 high-risk patients ran-
domized to surgical AVR in the PARTNER trial, the rate of
moderate or severe PVL was 1.9% at 1 year and 0.9% at 2
years.19 The present study with Edwards Intuity observed a
rate of moderate or severe PVL of 1.2% at 1 year. This rate
appears comparable to that after surgical AVR.
Study Limitations
The TRITON trial was a single-arm study without an
active comparator group. Hence, it might be vulnerable todiovascular Surgery c Volume 148, Number 6 2859
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were not excluded, the outcomes reflect the effect of a
learning curve. During the enrollment phase of the study,
considerable emphasis was placed on procedural training
and the sharing of best practices. Nonetheless, the possibil-
ity of performance bias could not be excluded. The clinical
endpoints were objectively defined a priori, and the out-
comes were independently determined by a clinical events
committee and an echocardiographic core laboratory.
Hence, the detection and measurement biases were miti-
gated but not eliminated. However compelling the data
appear to be at this interim analysis, the number of patients
followed up out to 3 years was small; hence, our findings
should be considered preliminary.CONCLUSIONS
The results of the TRITON trial have confirmed the
safety and efficacy of RDAVR using the Edwards Intuity
Valve System. At 3 years, the Intuity valve was associated
with a low mean transvalvular gradient and significant LV
mass regression. Moreover, compared with standard surgi-
cal bioprostheses, the Edwards Intuity might be associated
with larger EOAs in smaller valve sizes, a lower risk of
PPM owing to the structural valve design, and a low rate
of significant postoperative PVL. These hemodynamic ben-
efits were accompanied by significant improvements in pa-
tient functional status.
The authors thank Jill Trekell and Bruce Van Deman of Medical
and Clinical Affairs at Edwards Lifesciences, LLC, for their assis-
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Dr Y. Joseph Woo (Stanford, Calif). My disclosure is that last
year at Penn, I was the principal investigator for the Intuity valve
trial and had the opportunity to implant both first- and second-gen-
eration devices.
Dr Wahlers, I congratulate you and your co-investigators on
your excellent presentation, outstanding results, and pioneering
leadership in conveying innovative technologies into clinical
practice.
With this presentation and the report by Kocher and Borger,10
the TRITON team has demonstrated high procedural success,
shortened crossclamp and bypass times, enhanced minimally
invasive approaches, low paravalvular regurgitation rates,
excellent midterm clinical outcomes, LV mass regression, and
persistent single-digit mean gradients, with particular benefit in
the smaller annulus. I have 4 questions.
First, your hypothesis for the mechanism of generating a larger
EOA in the smaller annulus is that the balloon expandable stent
mechanically widens the LV outflow tract. Did you observe an
elevated incidence of transient conduction abnormalities or me-
chanical interference with mitral valve anterior leaflet mobility
or function?gery c December 2014
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I think the balloon expansion widens the outflow tract a little bit
but not permanently. We have not seen any dysfunctions leading to
pacemaker implantation, reflected by the pacemaker implant rate,
which was low or comparable to that with other prostheses.
Also, no interferencewith themitral valve anterior leaflet has been
reported to date. That might be also related to the, let us say, accept-
able height of the prosthesis. Thevalve is not sodeep sitting in theLV
outflow tract; thus, we have concluded that it does not interfere.
DrWoo.Thank you. Second, the size 19 Intuity valve compared
well with the reference echocardiographic data of the EOAs of
various other bioprostheses. However, when you study the rest
of the tabular data and you compare the Intuity valve against the
Magna, on which the Intuity was based, the data you presented re-
vealed that the size 23 and 25 Intuity EOAs, even with the
expanded LV outflow tract, were actually smaller than the corre-
sponding Magna EOAs. How would you reconcile this?
Dr Wahlers. Well, this is difficult to explain. What I can tell
you from the raw data is that we did not have all the values assessed
in every individual patient at all follow-up points. That might have
influenced the small sizes of the numbers, and we will have to wait
for larger patient numbers to correct for that.
DrWoo. Thank you. Third, based on either perception or direct
experience, would you be kind enough to offer any comparisons
between this device and another sutureless aortic bioprosthesis
widely available in Europe?
Dr Wahlers. That is a good point. I think the advantage of this
valve is that one has a conventional valve mounted on a stent, and
all other valves have new designs. That is the first point.
So, the new designs have to prove they will have the same dura-
bility as that of the Magna design, which has already been proved.
That addresses the first point.
The second point is that with the balloon dilatation of the LV
outflow tract, I think the fitting will be better in general compared
with that of the other valves available and, therefore, more
reproducible.The Journal of Thoracic and CarDr Woo. Thank you. Finally, given relative differences in the
magnitude of the procedure and device costs among transcatheter
aortic valve replacement, RDAVR, and standard bioprostheses,
where do you envision the ultimate niche for rapid deployment
or sutureless AVR?
Dr Wahlers. Well, this is a difficult question to answer. If one
can purchase this type of prosthesis for the same price as that of a
stented prosthesis, I would totally switch in the small sizes. So, it is
a question of the policy of the company regarding where to place
the costs.
It is really an advantage to use this valve in patients in whom
one wants to have a short clamp time. So, for redo procedures,
combined procedures in which one has impaired LV function,
and, perhaps, also in the small sizes, such as I mentioned, 19 or
21 mm, the valve might provide advantages with regard to the pa-
rameters I showed.
Dr Woo. Thank you again for your leadership in advancing the
field.
Dr Wahlers. Thank you very much for your kindness.
Dr Hans-Joachim Sch€afers (Homburg/Saar, Germany). One
quick question—you said in your presentation that the pacemaker
rate was 6%, which is somewhat greater than that after conven-
tional AVR, and valve related was 3%. How did you differentiate
between the 2?
Dr Wahlers. Let me explain the data. If the patient had pre-
existent disturbances, such bundle branch block, this led more
easily to a pacemaker being needed postoperatively. All other
pacemaker implantations were counted as directly related to
the valve implantation in patients who had not had these prob-
lems preoperatively.
We wanted to be very exact in our analysis, and if you
compare the percentage 6.9% for early pacemaker implantation,
this compares fairly well with the published data for pacemaker
rates in patients with a stented bioprosthesis. So, it is not
higher, which perhaps was suspected due to the stent design
before.diovascular Surgery c Volume 148, Number 6 2861
